Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist
- PMID: 10693868
- DOI: 10.1002/1529-0131(200002)43:2<289::AID-ANR8>3.0.CO;2-H
Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist
Abstract
Objective: To evaluate the recombinant adeno-associated virus vector encoding interleukin-1 receptor antagonist (rAAV-IL-1Ra) complementary DNA for its potential in the treatment and prevention of lipopolysaccharide (LPS)-induced arthritis.
Methods: The therapeutic effect of rAAV-IL-1Ra on arthritis was studied by injecting knees of Sprague-Dawley rats with LPS and rAAV-IL-1Ra and then evaluating the severity of arthritis by leukocyte counts in synovial fluid, histologic changes of synovium, and uptake of 67Ga citrate in joint tissue. To study the therapeutic effect on recurrent arthritis, we induced recurrent arthritis by a second injection of LPS 80 days after primary LPS and rAAV-IL-1Ra injections and then evaluated the severity of recurrent arthritis. To study the prevention of arthritis, rAAV-IL-1Ra was injected into normal joints. After 100 days, LPS was used to induce arthritis, and the severity of arthritis was evaluated.
Results: The production of the rAAV-IL-1Ra transgene was up-regulated by LPS-induced joint inflammation and proved to be efficacious in the therapeutic and preventative protocols. Not only primary but also recurrent arthritis could be suppressed by a single injection of rAAV-IL-1Ra. We found that the transgene expression of IL-1Ra could be reactivated by a second challenge with LPS delayed for 80 days after rAAV administration. The therapeutic level of IL-1Ra protein reached a mean +/- SD of 5.8+/-0.5 ng/ml in synovial fluid. In addition, the rAAV transgene persisted within normal joints for at least 100 days and could still be induced to express, after LPS insult, a high level of IL-1Ra (mean +/- SD 5.2+/-0.8 ng/ml) that prevented the occurrence of arthritis.
Conclusion: This gene therapy, by combining highly efficient and stable rAAV gene delivery, disease-regulated gene expression, and the antiinflammatory effect of IL-1Ra, provides a valuable approach for long-term protection against, and prevention of, arthritis.
Similar articles
-
C3-Tat/HIV-regulated intraarticular human interleukin-1 receptor antagonist gene therapy results in efficient inhibition of collagen-induced arthritis superior to cytomegalovirus-regulated expression of the same transgene.Arthritis Rheum. 2002 Jun;46(6):1661-70. doi: 10.1002/art.10481. Arthritis Rheum. 2002. PMID: 12115199
-
Suppression of experimental osteoarthritis by adenovirus-mediated double gene transfer.Chin Med J (Engl). 2006 Aug 20;119(16):1365-73. Chin Med J (Engl). 2006. PMID: 16934183
-
Intra-articular delivery of a herpes simplex virus IL-1Ra gene vector reduces inflammation in a rabbit model of arthritis.Gene Ther. 1999 Oct;6(10):1713-20. doi: 10.1038/sj.gt.3301014. Gene Ther. 1999. PMID: 10516720
-
Interleukin-1 receptor antagonist gene therapy for arthritis.Curr Opin Mol Ther. 1999 Aug;1(4):454-7. Curr Opin Mol Ther. 1999. PMID: 11713759 Review.
-
The role of cytokines in osteoarthritis pathophysiology.Biorheology. 2002;39(1-2):237-46. Biorheology. 2002. PMID: 12082286 Review.
Cited by
-
Reduction of experimental diabetic vascular leakage by delivery of angiostatin with a recombinant adeno-associated virus vector.Mol Vis. 2007 Jan 31;13:133-41. Mol Vis. 2007. PMID: 17293777 Free PMC article.
-
Gene therapy for rheumatoid arthritis.Curr Rheumatol Rep. 2001 Feb;3(1):79-85. doi: 10.1007/s11926-001-0054-x. Curr Rheumatol Rep. 2001. PMID: 11177774 Review.
-
IL-1 receptor antagonist: etiological and drug delivery systems overview.Inflamm Res. 2024 Dec;73(12):2231-2247. doi: 10.1007/s00011-024-01960-y. Epub 2024 Oct 26. Inflamm Res. 2024. PMID: 39455436 Review.
-
Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies.Mol Ther Methods Clin Dev. 2024 May 29;32(3):101273. doi: 10.1016/j.omtm.2024.101273. eCollection 2024 Sep 12. Mol Ther Methods Clin Dev. 2024. PMID: 39022744 Free PMC article.
-
Future of adenoviruses in the gene therapy of arthritis.Arthritis Res. 2001;3(3):142-6. doi: 10.1186/ar291. Epub 2001 Feb 19. Arthritis Res. 2001. PMID: 11299054 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources